HC Wainwright Brokers Boost Earnings Estimates for INO

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Analysts at HC Wainwright increased their Q1 2027 earnings per share (EPS) estimates for Inovio Pharmaceuticals in a report released on Monday, November 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.12) per share for the quarter, up from their prior forecast of ($0.15). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.12 EPS and FY2027 earnings at ($0.03) EPS.

Several other analysts have also recently commented on the stock. Zacks Research cut shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 12th. Weiss Ratings downgraded shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Piper Sandler restated an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a research report on Monday, August 3rd. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and increased their target price for the company from $1.80 to $3.00 in a report on Thursday, August 13th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Inovio Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $4.00.

Inovio Pharmaceuticals Stock Down 12.2%

NASDAQ:INO opened at $1.66 on Wednesday. Inovio Pharmaceuticals has a fifty-two week low of $0.56 and a fifty-two week high of $2.72. The firm’s fifty day simple moving average is $1.16 and its 200-day simple moving average is $1.27.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15.

Institutional Trading of Inovio Pharmaceuticals

Several large investors have recently modified their holdings of INO. Eversept Partners LP acquired a new position in shares of Inovio Pharmaceuticals during the 1st quarter worth approximately $1,802,000. Renaissance Technologies LLC lifted its stake in Inovio Pharmaceuticals by 16.4% in the 1st quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock valued at $1,120,000 after buying an additional 90,613 shares in the last quarter. Green Alpha Advisors LLC grew its holdings in Inovio Pharmaceuticals by 68.8% during the 3rd quarter. Green Alpha Advisors LLC now owns 114,857 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 46,802 shares during the last quarter. LexAurum Advisors LLC acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter valued at $118,000. Finally, Prime Capital Investment Advisors LLC grew its holdings in Inovio Pharmaceuticals by 312.4% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 53,510 shares during the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Key Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: The FDA granted accelerated approval to VOCERYQ, Inovio’s first commercial product, to reduce surgery frequency in adults with recurrent respiratory papillomatosis (RRP). The company says it is the first FDA-approved DNA medicine, providing a major regulatory and commercial milestone. Inovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor
• Positive Sentiment: HC Wainwright upgraded INO from Neutral to Buy and raised its 2027 earnings outlook. Its FY2027 EPS forecast improved to a loss of $0.03 from a loss of $0.21, and it projects positive EPS in Q3 and Q4; its price target is $5.00. The improved estimates may support sentiment, though they remain one analyst’s projections. HC Wainwright & Co. upgrades Inovio Pharmaceuticals to buy from neutral
• Neutral Sentiment: Inovio plans to report third-quarter results on November 10, which could provide investors with an update on finances and business plans. INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
• Negative Sentiment: The shares had surged sharply after the FDA announcement, leaving room for profit-taking and heightened volatility. Recent coverage also flags potential caveats around VOCERYQ’s data and the launch outlook, which may temper enthusiasm as investors assess its commercial prospects. Inovio’s VOCERYQ Data Cut Both Ways as Launch Clock Starts Ticking

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.